NOVARTIS: STARTS TENDER OFFER FOR AVEXIS17/04/2018
Swiss drugmaker Novartis said on Tuesday that it has begun a tender offer to acquire all of AveXis' common stock for 218 dollars a share in cash.
The tender offer will expire at midnight on 14 May, unless extended.
Last week Novartis said it would buy the Nasdaq-listed company in a deal worth 8.7 billion dollars, giving it the right to a gene therapy which could be used to fight spinal muscular atrophy.
Novartis also said this Tuesday that it would invest 100 million dollars to research and develop next-generation antimalarials as part of its commitment to eliminate malaria.